Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

April 30, 2003

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

DRUG

fludarabine phosphate

Trial Locations (18)

10021

Memorial Sloan-Kettering Cancer Center, New York

11040

Long Island Jewish Medical Center, New Hyde Park

21201

Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

60612

Rush-Presbyterian-St. Luke's Medical Center, Chicago

85724

Arizona Cancer Center, Tucson

90048

Cedars-Sinai Medical Center, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

20307-5000

Walter Reed Army Medical Center, Washington D.C.

52242-1009

Holden Comprehensive Cancer Center, Iowa City

02111

Tuft-New England Medical Center, Boston

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

45267-0502

Barrett Cancer Center, Cincinnati

T6G 1Z2

Cross Cancer Institute, Edmonton

L8N 3Z5

Chedoke-McMaster Hospitals, Hamilton

SE-141 86

Huddinge University Hospital, Stockholm

EC1A 7BE

Saint Bartholomew's Hospital, London

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00020800 - Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter